| Date | Action | Conf | Host / episode | Summary | 7d | 30d | 90d |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | MENTIONED | LOW | Rob Black Show Markets Fall As Losses Accelerate |
AbbVie was described as having a path to strong long-term growth across immunology, oncology, neuroscience, and obesity. [audio] | +0.8% | — | — |
| 2026-08-20 | MENTIONED | MEDIUM | Rob Black Show Markets Drop Hurt By Rising Treasury Yields |
Named alongside Pfizer as investing heavily in next-generation antibody drug conjugates, one of the hottest areas in oncology. [audio] | -1.4% | +0.8% | — |
| 2026-07-20 | WATCH | MEDIUM | Rob Black Show Oil Prices Fluctuated |
AbbVie cited as a large pharmaceutical company interested in psychedelics due to its psychiatric medicine business and financial resources. [audio] | +1.4% | +5.0% | — |
| 2026-07-17 | MENTIONED | MEDIUM | Rob Black Show Financial Planning That You Never Knew |
AbbVie mentioned as a large pharmaceutical company interested in psychedelic medicine. [audio] | +1.9% | -2.0% | — |
| 2026-06-29 | BUY | MEDIUM | Rob Black Show Afternoon podcast 6-29-26 |
AbbVie traded at all-time highs; positive sentiment implied. [audio] | +0.2% | +4.3% | +4.7% |
| 2026-06-22 | MENTIONED | LOW | Rob Black Show Declines In Technology Stocks |
AbbVie is buying Apogee Therapeutics for $10.9 billion to strengthen its immunology portfolio. [audio] | +10.6% | +10.9% | +15.6% |
| 2026-05-29 | BUY | MEDIUM | Rob Black Show Thinking About A Shopping List |
The host recommends buying AbbVie, citing a low P/E ratio and the potential for AI-driven growth. [audio] | +4.4% | +16.4% | +19.4% |
| 2026-05-11 | MENTIONED | MEDIUM | Rob Black Show Fresh Record Bolstered By Key Tech Stocks |
[audio] | +3.3% | +10.9% | +22.2% |